Colorectal Cancer | Disease Landscape & Forecast | G7 | 2021
Chemotherapy remains the dominant cornerstone of colorectal cancer treatment and is prescribed with angiogenesis or EGFR inhibitors in the metastatic setting. Patient biomarker status (e.g., BRAF, RAS, MSI-H/dMMR) and tumor location play a key role in guiding treatment selection. Immune checkpoint inhibitors (Merck & Co.’s Keytruda and Bristol Myers Squibb’s Opdivo and Yervoy) and BRAF inhibitors (Array BioPharma / Pfizer’s Braftovi) have recently emerged as novel options and will see robust uptake in eligible patients. Further personalization of treatment will ensure continued uptake of currently approved therapies over the 2020-2030 forecast period. We also expect several novel agents and combinations to impact the market and help address the high unmet need for additional and more-efficacious treatments.
QUESTIONS ANSWERED
- How large are the drug-treatable colorectal cancer populations? How do patient populations differ by disease stage and key biomarkers?
- What are key opinion leaders’ views on current and emerging therapies, and what strategies are companies pursuing to secure uptake and share in the colorectal cancer market?
- Which pipeline products are poised to launch for colorectal cancer, and what unmet needs do they address?
- What are the key drivers and constraints on the colorectal cancer therapy market, and how will the major markets evolve over the 10-year forecast period?
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
SOLUTION ENHANCEMENT
Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.
